A New Donors' Cyp3a5 and Recipients' Cyp3a4 Cluster Predicting Tacrolimus Disposition, and New-Onset Hypertension in Chinese Liver Transplant Patients
Yuan Liu,Tao Zhang,Xiaoqing Zhang,Ling Ye,Haitao Gu,Lin Zhong,Hongcheng Sun,Chenlong Song,Zhihai Peng,Junwei Fan
DOI: https://doi.org/10.18632/oncotarget.19606
2017-01-01
Oncotarget
Abstract:Aim: The purpose of the current study was to investigate individualized therapy of tacrolimus (Tac), as well as complications after liver transplantation (LT) with the known genetic determinants and clinical factors.Methods: In this retrospective study, two cohorts (n = 170) from the China Liver Transplant Registry (CLTR) database from July 2007 to March 2015 were included.Results: Both donors' CYP3A5*3 and recipients' CYP3A4*1G had a correlation with Tac pharmacokinetics at four weeks (all P < 0.05), except recipients' CYP3A4*1G nearly had an association at week 2 (P = 0.055). The model of donors' CYP3A5*3, recipients' CYP3A4*1G, and total bilirubin (TBL),for the prediction of Tac disposition, was better than donors' CYP3A5*3 only at week 1, 2, and 3 (P = 0.010, P = 0.007, and P = 0.010, respectively), but not apparent at week 4 (P = 0.297). Besides, when the P value was greater than or equal to 0.6685 after considering the false-positive rate R = 10%, the patients were considered to have a faster metabolism, according to the mentioned model. Interestingly, we found that if more than or equal to two alleles A were present in the combination of donors' CYP3A5*3 and recipients' CYP3A4*1G genotype, there was a lower Tac C/D ration at week 1, 2, and 3 (P < 0.001, P = 0.001, and P < 0.001), except at week 4 (P = 0.082), and the probability of new-onset hypertension was lesser (P < 0.001).Conclusions: These data provided a potential basis for a comprehensive approach to predicting the Tac dose requirement in individual patients and provided a strategy for the effective prevention, early diagnosis of new-onset hypertension in Chinese LT recipients.